Samsung Bioepis to Present Post-hoc Analysis of Phase 3
Post-hoc analysis of Phase 3 study to highlight transfusion avoidance results of SB12 compared to reference eculizumab-treated groups INCHEON, Korea, May ...
Source: globenewswire.com
📰 Accessed May News
Page 2 - Accessed May News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Accessed May. Real-time updates on events, politics, business and more.
How to finance a recreational vehicle: RV loans, alternatives and tips for getting out on the open road
Secured loans and financing alternatives for buying a new or used RV, including how to qualify and factors to consider before hitting the open road.
Source: aol.com
Lp(a), LDL management, health system quality metrics and more in spotlight at NLA 2024
The National Lipid Association Scientific Sessions will be held Thursday to Sunday and will spotlight emerging areas of research such as “cardio-rheumatology,” a renewed push to reinstate LDL as a health system quality metric and more. Christie M. Ballantyne, MD, FACC, FACP, FAHA, FNLA, chief of the section of cardiovascular research and professor of medicine at Baylor College of
Source: healio.com
FDA Approves Clonidine Hydrochloride For Treatment of ADHD in Pediatric Patients
The treatment is the first liquid non-stimulant for attention deficit hyperactivity disorder to be approved in the United States.
Ann Childress National Center Tris Pharma Psychiatry Investigation Clinical Global Impression Severity Clinical Global Impression Improvement
Source: pharmacytimes.com
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
U.S. FDA approves new one pill, once-daily AUSTEDO XR tablets AUSTEDO XR offers more flexibility with the most once-daily doses of any vesicular monoamine transporter 2 inhibitor for effective...
United States Dell Faulkingham Rakesh Jain Clin Psychopharmacol National Institute Of Mental Health Texas Tech University School Of Medicine
Source: marketscreener.com
Telix Submits NDA for New Prostate Cancer Imaging Agent
MELBOURNE, Australia, May 28, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submi...
Source: businessinsider.com
New Research: Revealing the True Duration of Binge-Eating Disorder
Investigators at McLean Hospital found 61% and 45% of individuals still experiencing binge-eating disorder after 2.5 and 5 years after their initial diagnoses, respectively.
Kristin Javaras Wanlee Adobestock Division Of Women Mental Health At Mclean National Institute Of Mental Health Mclean Hospital Mental Health
Source: psychiatrictimes.com
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous nonsmall cell lung cancer in TROPIONLung01 Phase III trial
Highlevel overall survival OS results from the TROPIONLung01 Phase III trial which previously met the dual primary endpoint of progressionfree survival PFS numerically favoured datopotamab deruxtecan DatoDXd compared to docetaxel in the overall trial population of patients with locally advanced or metastatic nonsmall cell lung cancer NSCLC treated with at least one prior line of therapy.
Source: businesswireindia.com
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label...
Source: prnewswire.com
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1%...
Source: prnewswire.com